Drug Profile
Research programme: trastuzumab biosimilar - ISU Abxis
Alternative Names: ISU103Latest Information Update: 15 Jan 2022
Price :
$50
*
At a glance
- Originator ISU Abxis
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action ERBB 2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Breast cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Breast-cancer in South Korea (IV, Infusion)
- 12 Mar 2014 Preclinical development is ongoing in South Korea
- 31 Jan 2012 Preclinical trials in Breast cancer in South Korea (IV)